GlassScriptPhysician profile
Christopher Pumill
NPI 1467815159
$2,189.94
in general payments reported to CMS, 2019-2025
16 companies · $428 in 2025
The $428 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $621 · 2023: $719 · 2024: $422 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,568.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $423.53 | 2022-2025 | Ffrct |
| Astrazeneca Pharmaceuticals LP | $280.43 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $236.42 | 2022-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $233.71 | 2024-2025 | |
| Amgen INC. | $199.01 | 2022-2025 | Repatha, Repatha |
| Abbott Laboratories | $174.62 | 2022-2023 | Mitraclip |
| Bridgebio Pharma, INC. | $136.84 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $119.39 | 2022 | |
| Novo Nordisk INC | $114.41 | 2023 | |
| Janssen Pharmaceuticals, INC | $76.68 | 2023-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $63.41 | 2023-2024 | Verquvo |
| Pfizer INC. | $60.95 | 2023-2025 | |
| Cleerly, INC. | $21.33 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Alnylam Pharmaceuticals INC. | $18.63 | 2025 | Amvuttra |
| Lilly USA, LLC | $16.02 | 2025 | Zepbound |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $14.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Pumill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.